Patent US3559181A successfully refreshed from Google Patents.
US5273738A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiation delivery to lymphoid and marrow tissues
Assignee: Fred Hutchinson Cancer Center
•
Filing: 1990-03-03
•
Granted: 1993-12-28
•
Expires: 2010-03-03
Abstract
Abstract A method of selectively delivering radiation homogeneously to lymphoid and marrow tissues in vivo including the step of administering an effective dose of a radiolabeled immunological binding partner of a T-200 antigen to a patient is disclosed. Also disclosed are immunological binding partners and compositions based thereon for carrying out the method.
Inventors
- 👤 Dana C. Matthews
- 👤 Irwin D. Bernstein
- 👤 John A. Hansen
- 👤 Fred R. Appelbaum
- 👤 Claudio Anasetti
- 👤 Paul J. Martin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:57
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1027
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
70 words
A method of selectively delivering radiation homogenously to lymphoid and marrow tissues in vivo, comprising: administering to a patient an effective dose of a radiolabeled immunological binding partner consisting essentially of an antigen-binding site capable of binding to a T-200 antigen, wherein said effective dose results in a selective delivery of more radioactivity to bone marrow tissue than to liver or lung tissue at about 48 hours after said administering.
Claim 2
Independent Claim
70 words
A method of selectively delivering radiation homogenously to lymphoid and marrow tissues in vivo, comprising: administering to a patient an effective dose of a radiolabeled immunological binding partner consisting essentially of an antigen-binding site capable of binding to a T-200 antigen, wherein said effective dose results in a selective delivery of more radioactivity to bone marrow tissue than to liver or lung tissue at about 48 hours after said administering.
Claim 3
Dependent Claim
19 words
The method according to claim 1, wherein the immunological binding partner is a monoclonal antibody against a T-200 antigen.
Claim 4
Dependent Claim
12 words
The method according to claim 2, wherein said monoclonal antibody is murine.
Claim 5
Dependent Claim
52 words
The method according to claim 1, wherein said T-200 antigen is a member of a family of membrane glycoproteins having a molecular weight ranging from about 180 kD to about 220 kD as determined by SDS-PAGE, said antigen being expressed on substantially all hematopoietic cells except erythroid precursors, mature erythrocytes, and platelets.
Claim 6
Dependent Claim
26 words
The method according to claim 1, wherein said immunological binding partner is radiolabeled with a radioisotope of iodine, bromine, fluorine, astatine, samarium, rhenium, holmium, or yttrium.
Claim 7
Dependent Claim
16 words
The method according to claim 5, wherein the immunological binding partner is radiolabeled with 131 I.
Claim 8
Dependent Claim
26 words
The method according to claim 1, wherein said effective dose ranges from about 0.1 mg/kg body weight to about 10 mg/kg body weight of said patient.
Claim 9
Dependent Claim
40 words
The method of claim 1, wherein said administering results in a selective delivery of at least about 2 fold more radioactivity to spleen and lymph node tissue than to liver and lung tissue at about 48 hours after said administering.
Claim 10
Dependent Claim
12 words
The method according to claim 1, wherein said patient is a human.
Claim 11
Dependent Claim
14 words
The method according to claim 1, wherein said patient has a bone marrow disease.
Claim 12
Dependent Claim
32 words
The method according to claim 1, wherein said patient has at least one of acute lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, myeloma, or chronic lymphocytic leukemia.
Claim 13
Dependent Claim
16 words
The method according to claim 1, wherein said patient is in need of a marrow transplant.
Claim 14
Dependent Claim
13 words
The method according to claim 1, wherein said patient has a hematologic malignancy.
Claim 15
Dependent Claim
45 words
The method according to claim 1, wherein said immunological binding partner is a monoclonal antibody, or antigen-binding site thereof, produced by a hybridoma having the identifying characteristics of BC8 or 9.4, which are deposited at the ATCC under accession numbers HB10507 (BC8) and HB10508 (9.4).
References Cited (Backward Citations)
WO1982001192A1
Cited
US4582797A
Cited
US4626507A
Cited
US4911690A
Cited
US5091178A
Cited
US5028424A
Cited
US5002869A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-12-27 | 1997-06-28 | 1997-12-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-12-27 | 2001-06-28 | 2001-12-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-12-27 | 2005-06-28 | 2005-12-28 | $7700.00 | Window Closed / Lapsed |